John  Lunger net worth and biography

John Lunger Biography and Net Worth

John Lunger has served as our Chief Patient Supply Officer since August 2019 and is a member of our Executive Team. John leads the teams responsible for producing and delivering products to patients, accelerating supply execution, and optimizing the supply chain to be ready for commercialization. Prior to joining our Executive Team, he was Senior Vice President, Manufacturing and Supply Chain at Adaptimmune, having joined the Company in March of 2017. In this role, he was responsible for clinical manufacturing and global supply of Adaptimmune’s autologous T-cell therapy products.

Previously, John was Head of Supply Chain and Commercial Product Supply at Merrimack Pharmaceuticals where he led clinical and commercial supply chain as well as the cross functional supply team for Merrimack’s first commercial product launched in October of 2015.  Earlier in his career, he held various senior manufacturing, operational, and strategy roles with VWR International, Pfizer, and Wyeth Pharmaceuticals. In his nearly 10 years with Wyeth he held a number of leadership positions, including operations and supply chain strategy, supply management, procurement and strategic sourcing, business systems implementation, generic pharmaceutical business management, and site operations management in a pharmaceutical manufacturing plant in Ireland. John began his career serving as a nuclear trained officer on a U.S. Navy submarine followed by strategic consulting with Accenture.

John holds a Bachelor of Science degree (with distinction) in Ocean Engineering from the US Naval Academy and an MBA in economics and operations management from the University of Chicago’s Booth School of Business.

What is John Lunger's net worth?

The estimated net worth of John Lunger is at least $5,001.08 as of August 1st, 2023. Mr. Lunger owns 4,718 shares of Adaptimmune Therapeutics stock worth more than $5,001 as of April 25th. This net worth estimate does not reflect any other assets that Mr. Lunger may own. Learn More about John Lunger's net worth.

How do I contact John Lunger?

The corporate mailing address for Mr. Lunger and other Adaptimmune Therapeutics executives is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. Adaptimmune Therapeutics can also be reached via phone at 441235430000 and via email at [email protected]. Learn More on John Lunger's contact information.

Has John Lunger been buying or selling shares of Adaptimmune Therapeutics?

John Lunger has not been actively trading shares of Adaptimmune Therapeutics over the course of the past ninety days. Most recently, John Lunger sold 3,096 shares of the business's stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $0.91, for a transaction totalling $2,817.36. Following the completion of the sale, the insider now directly owns 4,718 shares of the company's stock, valued at $4,293.38. Learn More on John Lunger's trading history.

Who are Adaptimmune Therapeutics' active insiders?

Adaptimmune Therapeutics' insider roster includes Willaim Bertrand, Jr. (COO), John Lunger (Insider), Elliot Norry (Insider), and Adrian Rawcliffe (CEO). Learn More on Adaptimmune Therapeutics' active insiders.

Are insiders buying or selling shares of Adaptimmune Therapeutics?

During the last year, insiders at the biotechnology company sold shares 10 times. They sold a total of 92,980 shares worth more than $80,940.12. The most recent insider tranaction occured on January, 16th when CEO Adrian Rawcliffe sold 9,304 shares worth more than $7,350.16. Insiders at Adaptimmune Therapeutics own 12.4% of the company. Learn More about insider trades at Adaptimmune Therapeutics.

Information on this page was last updated on 1/16/2024.

John Lunger Insider Trading History at Adaptimmune Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/1/2023Sell3,096$0.91$2,817.364,718View SEC Filing Icon  
1/17/2023Sell4,440$1.86$8,258.407,264View SEC Filing Icon  
1/11/2023Sell3,843$1.75$6,725.256,270View SEC Filing Icon  
1/4/2023Sell1,100$1.69$1,859.001,725View SEC Filing Icon  
8/1/2022Sell2,983$1.77$5,279.914,829View SEC Filing Icon  
7/5/2022Sell1,973$1.68$3,314.643,104View SEC Filing Icon  
1/12/2022Sell1,076$3.54$3,809.04View SEC Filing Icon  
1/4/2022Sell1,070$4.06$4,344.20View SEC Filing Icon  
8/2/2021Sell2,939$3.58$10,521.62View SEC Filing Icon  
1/12/2021Sell1,058$6.15$6,506.70View SEC Filing Icon  
1/4/2021Sell1,065$5.33$5,676.45View SEC Filing Icon  
8/3/2020Sell4,823$9.25$44,612.75View SEC Filing Icon  
1/6/2020Sell1,148$1.20$1,377.60View SEC Filing Icon  
See Full Table

John Lunger Buying and Selling Activity at Adaptimmune Therapeutics

This chart shows John Lunger's buying and selling at Adaptimmune Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Adaptimmune Therapeutics Company Overview

Adaptimmune Therapeutics logo
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Read More

Today's Range

Now: $1.06
Low: $1.04
High: $1.10

50 Day Range

MA: $1.39
Low: $0.90
High: $1.75

2 Week Range

Now: $1.06
Low: $0.42
High: $2.05

Volume

302,573 shs

Average Volume

1,751,436 shs

Market Capitalization

$1.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.39